Altered glycolysis is a hallmark of diseases including diabetes and cancer. Despite intensive study of the contributions of individual glycolytic enzymes, systems-level analyses of flux control through glycolysis remain limited. Here, we overexpress in two mammalian cell lines the individual enzymes catalyzing each of the 12 steps linking extracellular glucose to excreted lactate, and find substantial flux control at four steps: glucose import, hexokinase, phosphofructokinase, and lactate export (and not at any steps of lower glycolysis). The four flux-controlling steps are specifically upregulated by the Ras oncogene: optogenetic Ras activation rapidly induces the transcription of isozymes catalyzing these four steps and enhances glycolysis. At least one isozyme catalyzing each of these four steps is consistently elevated in human tumors. Thus, in the studied contexts, flux control in glycolysis is concentrated in four key enzymatic steps. Upregulation of these steps in tumors likely underlies the Warburg effect.
In Brief
Here, we perform a systematic analysis of glycolytic flux control in mammalian cells. We identify four key flux-controlling steps: glucose import and phosphorylation, fructose-1,6bisphosphate production, and lactate export. In contrast, enzyme steps in lower glycolysis do not control pathway flux. Activation of glycolysis in cancer and immune cells is associated with enhanced expression of enzymes catalyzing these four key fluxcontrolling steps.
INTRODUCTION
Glycolysis provides cellular energy and metabolic precursors for biomass production. Seminal studies performed over the past hundred years have elucidated the mechanism and regulation of the ten enzymatic steps of glycolysis, which together catalyze the breakdown of glucose into two molecules of pyruvate. These ten enzymatic steps, together with the lactate dehydrogenase reaction and two transport events at the plasma membrane (i.e., the uptake of glucose via glucose transporters and the excretion of lactate via monocarboxylate transporters) constitute the 13 potential steps for directly controlling glycolytic flux.
Control of glycolytic rate plays an important role in mammalian physiology, contributing to circulating glucose homeostasis and providing ATP and/or biomass building blocks in contexts such as cell proliferation, immune activation, and angiogenesis (Buck et al., 2017; De Bock et al., 2013; Everts et al., 2014; Yu et al., 2017) . Dysregulated glucose metabolism is a hallmark of diseases including diabetes and cancer.
Cancer cells extensively ferment glucose even in the presence of adequate oxygen (Warburg, 1956) . While initially attributed by Warburg to defective mitochondria, it is now clear that most cancer cells have functional mitochondria that account for much of their ATP production (DeBerardinis and Chandel, 2016; Fan et al., 2014; Vander Heiden and DeBerardinis, 2017; Zong et al., 2016; Zu and Guppy, 2004) . Accordingly, we use the term Warburg effect to refer to rapid aerobic glycolysis in cancer cells, irrespective of their utilization of oxidative phosphorylation. It has been argued that the Warburg effect promotes tumor growth by satisfying cancer cells' high demand for both energy and central carbon metabolites for biosynthesis (Liberti and Locasale, 2016) . The Warburg effect can be triggered both by oncogenic mutations (e.g., in Ras, PI3K/Akt, c-Myc) and by environmental cues (e.g., growth factors) (Gaglio et al., 2011; Hay, 2016; Vander Heiden et al., 2009; Hu et al., 2016; Lunt and Vander Heiden, 2011; Shim et al., 1997; Yu et al., 2017) .
Consistent with their high utilization of glycolysis, cancers and other proliferating cells exhibit increased expression of many glycolytic enzymes (Vander Heiden et al., 2009) . High expression of the glucose transporters GLUT1 and GLUT3 is associated with augmented glucose uptake and oncogenic growth (Birsoy et al., 2014; Onodera et al., 2014; Yun et al., 2009) . Elevated activities of hexokinase and phosphofructokinase favor tumor initiation, immune cell activation, and angiogenesis (De Bock et al., 2013; Everts et al., 2014; Patra et al., 2013; Ros and Schulze, 2013; Webb et al., 2015; Yi et al., 2012; Ying et al., 2012; Yu et al., 2017) . Aldolase A (ALDOA) has been shown to boost glycolysis upon phosphoinositide 3-kinase (PI3K)/Akt signaling (Hu et al., 2016) . When upper glycolysis is activated in cancer cells, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been reported to become a rate-limiting pathway step (Shestov et al., 2014) . The importance of the final enzyme involved in pyruvate production, pyruvate kinase, to glycolytic flux control remains controversial. Earlier studies advocated for Figure 1 . Glycolytic Flux Is Controlled by Glucose Import, Fructose-1,6-Bisphopshate Production, and Lactate Export (A) Experimental setup used to determine glycolytic flux control. Enzymes were individually overexpressed in iBMK cells and change in lactate secretion (glycolytic flux) was assessed 24 hr post transfection; f J E is the ratio between lactate secretion in enzyme-overexpressing cells versus vector-control cells. (B) Western blot showing that the expression dynamics of different glycolytic enzymes is similar (see Figure S1 for additional enzymes). (C) Single glycolytic enzyme expression did not change the ratio of produced lactate to consumed glucose. Means of two biological replicates per condition are plotted. Parental, Akt, and Ras stably expressing iBMK cells are colored in red. (D and E) Change in lactate secretion compared with vector control upon individual overexpression of glycolytic enzymes (in DMEM supplemented with 10% dialyzed fetal bovine serum and 5 mM or 25 mM glucose as indicated) (D) and associated flux-control coefficients according to the equation in (A) (for enzymes (legend continued on next page) the PKM2 isoform as a key driver of the Warburg effect, but recent evidence suggests that the situation is more complex (Bluemlein et al., 2011; Christofk et al., 2008; Dayton et al., 2016) . Finally, lactate dehydrogenase A (LDHA) has been implicated in c-Myc-mediated transformation (Shim et al., 1997) . Thus, nearly every enzyme linking glucose to lactate has been associated in some study with enhancing glycolytic flux.
Despite this extensive literature, a unified view of glycolytic flux control is lacking. In particular, the key glycolytic enzymes whose upregulation is required for flux enhancement remains unclear. This in part likely reflects variation in flux control across cell lines and environmental conditions. It might also, however, reflect a failure to comprehensively experimentally probe the pathway. Specifically, to obtain a thorough understanding of flux control in any given biochemical pathway, it is valuable to systematically perturb each component to assess its contribution to overall pathway control. However, previous experiments have largely focused on the role of individual glycolytic enzymes in isolation, and efforts to interrogate the entire pathway have primarily been theoretical and computational (Dai et al., 2016; Shestov et al., 2014) .
Here we examine, in two mouse cell lines, the degree of flux control residing in each step of glycolysis by systematically overexpressing enzymes that catalyze every glycolytic step, and by subsequently analyzing pathway flux. We find that across all enzymes tested, only four steps show significant flux control: In both cell lines, flux is controlled by the two committed steps of upper glycolysis (i.e., hexokinase and phosphofructokinase, with the complication that excessive hexokinase leads to energy stress). In one cell line but not the other, glucose import and lactate export also control flux. In both cell lines, the enzymes of lower glycolysis did not control glycolytic flux. We further show that acute optogenetic stimulation of Ras is sufficient to enhance glycolytic flux and that Ras activates the transcription of genes encoding for the same four steps revealed in our overexpression experiments. Finally, analysis of expression data from solid tumors and paired normal tissue samples reveals a transcriptional signature in which gene isoforms from each of these four steps are strongly and consistently upregulated across tumor types. While other enzymes may play additional regulatory roles in certain contexts, our findings show that glycolytic flux is controlled at a small number of pathway steps whose upregulation underlies the Warburg effect.
RESULTS

Systematic Enzyme Overexpression Can Reveal Glycolytic Flux Control
To systematically identify flux-controlling steps in glycolysis, we transiently overexpressed at least one human isozyme cata-lyzing every pathway step from import of extracellular glucose to secretion of lactate. Isozymes were chosen based on their high expression in glycolytic cells and human cancers (Hay, 2016) . We tested multiple isozymes of glucose transporters, phosphofructokinases, and pyruvate kinases. In addition, we included fructose-1,6-bisphosphatase (FBP1), pyruvate dehydrogenase kinase 1 (PDK1), and the four isozymes of the phosphofructokinase 2 (PFK2) family, which phosphorylate fructose-6-phosphate to make fructose-2,6-bisphosphate, a key activator of the glycolytic enzyme phosphofructokinase 1 (PFK1). PFK2 isozymes, which are known as PFKFB1-4, are bifunctional and also contain phosphatase domains that can consume fructose-2,6-bisphosphate (Ros and Schulze, 2013) . In total, we tested a set of 24 glycolysis-related genes. GFP was used as a negative control.
Our initial experiments were performed in immortalized baby mouse kidney cells (iBMK), which were selected for their metabolic characterization (Fan et al., 2014) and high transfection efficiency. To minimize possible metabolic alterations induced by adaptation, we measured glycolytic flux within the first 30 hr after transfection (Figures 1A, S1A, and S1B). Experiments were performed in both 25 mM glucose (common tissue culture concentration) and 5 mM glucose (typical circulating concentration in human).
Each of the tested constructs was well expressed, with substantial accumulation of the recombinant protein by 18 hr and corresponding 5-fold or greater enhancement of the enzyme's catalytic activity as measured in lysates (Figures 1B, S1C, S1D, and S1E). Overexpression of some individual glycolytic enzymes altered both glucose consumption and lactate secretion, but none significantly changed the ratio of glucose uptake to lactate secretion: cells excreted about 82% of incoming glucose carbon as lactate (Figures 1C, S1F, and S1G). Even greater conversion of glucose to lactate was observed in cells expressing oncogenic mutant Ras (H-Ras V12G ; Figure 1C ), consistent with previous reports that oncogenic Ras inhibits pyruvate oxidation and enhances glycolytic flux (Fan et al., 2014; Gaglio et al., 2011) .
Based on the nearly constant ratio of glucose uptake to lactate secretion across the cell lines, use of either metric leads to the same conclusions about glycolytic flux. Yet measurements of lactate secretion are more precise ( Figure S1F ), as the fractional drop in extracellular glucose over 6 hr is small and thus difficult to measure. Accordingly, in all subsequent analyses we used lactate secretion as a proxy for glycolytic flux. The uncertainty in the glucose uptake measurements was too large for us to determine whether the absolute flux of glucose carbon not being excreted as lactate tracks with glycolytic flux.
The extent to which a particular pathway step affects glycolytic flux can be expressed as a flux-control coefficient increasing glycolytic flux) (E). Blue and red indicate statistically significant increases and decreases, respectively (q < 0.05). Means and 95% confidence intervals (n R 6 biological replicates from at least two independent experiments) are plotted. ðC J E Þ: the fractional change in glycolytic flux (J) induced by a given fractional change in enzyme catalytic activity (E) (Fell, 1998; Heinrich and Rapoport, 1974; Kacser and Burns, 1973) ,
Experimentally, measurement of C J E based on Equation 1 is difficult. It requires quantitating small changes in both fluxes and enzyme activities. Fortunately, C J E can be approximated based on the fold change in flux ðf J E Þ (measured as the flux ratio between cells with enhanced versus basal enzyme activity) that occurs upon massively increasing the activity of a given enzymatic step (Small and Kacser, 1993a ) (see STAR Methods),
Note that dramatically increasing the activity of a given step does not correspondingly increase pathway flux, unless that is the sole rate-limiting pathway step, in which case C J E z1. For steps that are not rate controlling, the pathway may not respond, and C J E z0.
Flux Is Controlled by Glucose Import, Phosphofructokinase, and Lactate Export Of the 24 individually overexpressed genes, only seven significantly increased glycolytic flux in iBMK cells cultured in both high-and low-glucose media ( Figures 1D and 1E ): GLUT1, GLUT3, and GLUT5 (glucose transporters); MCT4 (lactate transporter); PFKP (phosphofructokinase; PFK1); and PFKFB1 and PFKFB3 (phosphofructo-2-kinase/fructose-2,6-biphosphatases; PFK2). The flux-control coefficient for PFKP was comparable with previous literature values determined in other mammalian cells (Small and Kacser, 1993a; Torres et al., 1986) . Our results are in agreement with literature pointing to the importance of glucose uptake and FBP production in controlling glycolytic flux (Birsoy et al., 2014; Onodera et al., 2014; Ros and Schulze, 2013; Webb et al., 2015; Yi et al., 2012; Ying et al., 2012; Yun et al., 2009) . In contrast, no enzymes in lower glycolysis significantly affected flux, including enzymes suggested in prior literature as inducers of the Warburg effect: ALDOA (aldolase), GAPDH, PGK (phosphoglycerate kinase), PKM1 and PKM2 (pyruvate kinases), and LDHA (lactate dehydrogenase). Nevertheless, we did observe significant flux control in the lactate export step, as overexpression of MCT4 led to a substantial increase in glycolytic flux ( Figures 1C-1E ).
Certain genes, such as PKM2 and LDHA, have been classically associated with the Warburg effect but did not show any impact on glycolytic metabolism here. To rule out that these genes promote Warburg metabolism by suppressing oxidative phosphorylation or impairing glucose entry into the tricarboxylic acid (TCA) cycle, we also examined oxygen consumption rate and contribution of glucose carbon to TCA intermediates. Although there was a trend toward higher oxygen consumption with GLUT3 overexpression, the oxygen consumption rate did not vary significantly in response to overexpression of GLUT3, PFKP, GAPDH, PKM2, LDHA, or MCT4 ( Figure S1H ). Glucose contribution to TCA was slightly but significantly decreased by PFKP overexpression but not affected by any other of these genes ( Figure S1I ). Thus, the GLUT, PFK, and MCT steps pro-mote glycolytic flux, while most other steps neither drive glycolytic flux nor modulate glucose oxidation.
The summation theorem of metabolic control analysis states that the sum of the flux-control coefficients in a linear pathway must equal 1 (Kacser and Burns, 1973) . This theorem refers to the sum of flux control across the pathway steps, not across isozymes. In our case, we observe flux control of about 30% for glucose uptake, 30% for FBP production (either via expression of phosphofructokinase or its activators PFKFB1 or PFKFB3), and 40% for lactate export, together summing to approximately 100% ( Figure 1F ). Thus, our data are roughly consistent with the summation theorem.
We then tested the potential to further activate glycolytic flux in iBMK cells grown in 25 mM glucose by coexpressing GLUT3, PFKP, and MCT4 ( Figure 1G ). The ATP synthase inhibitor oligomycin was used as a positive control (Huijing and Slater, 1961; Lardy et al., 1958) . Combined overexpression of GLUT3, PFKP, and MCT4 triggered a 2-fold increase in glycolytic flux, which is comparable with oligomycin and significantly greater than any individual gene on its own ( Figure 1G ). Similar increases in glycolytic flux were obtained with coexpression of either transporter with PFKP, but not the two transporters together. The roles for glucose import, phosphofructokinase, and lactate export in controlling iBMK cell glycolysis are highlighted in Figure 1H .
PFK2 Isoforms Exhibit Divergent Effects on Glycolytic Flux
Overexpression of 5 of the 24 tested genes significantly decreased glycolytic flux in both glucose conditions ( Figure 1D ). The reduction in glycolytic flux observed upon overexpression of fructose-1,6-bisphosphate phosphatase (FBP1) is consistent with its role in gluconeogenesis and inhibition of tumor progression (Li et al., 2014; Tejwani, 1983) . We also captured the welldocumented anti-glycolytic function of the TP53-induced glycolysis and apoptosis regulator (TIGAR) (Bensaad et al., 2006) . In contrast, we were surprised to find that hexokinase 2 (HK2) overexpression decreased flux, an observation that results from energy stress based on its excessive overexpression, as described below.
Another anti-glycolytic gene was the phosphofructokinase-2 isozyme PFKFB2. This contrasted with PFKFB1 and PFKFB3, which as expected increased glycolysis, and PFKFB4, which had no discernible effect ( Figure 1D ). While PFK2 isoforms are generally considered pro-glycolytic, their impact on glycolysis depends on their balance of kinase and phosphatase activity. Recent in vitro biochemistry studies have assigned the highest kinase-to-phosphatase ratio to the PFKFB3 isoform (>700:1) (Ros and Schulze, 2013) , which we found most strongly induced glycolytic flux. Existing biochemical data on the other three PFK2 isoforms, however, does not explain their divergent glycolytic flux phenotypes, as their in vitro kinase and phosphatase activities are similar. Our results highlight the functional diversity of PFK2 isoforms in cells, with the PFKFB2 isozyme acting to slow glycolysis.
Intracellular FBP Concentration Mirrors Glycolytic Flux
To explore potential connections between enzyme induction, flux, and metabolite levels, we measured changes in glycolytic intermediate levels by liquid chromatography-mass spectrometry. (legend continued on next page) These metabolomics data confirmed the functional activities of the overexpressed enzymes ( Figure 2A ). For example, overexpression of PFKP led to a decrease in fructose-6-phosphate (F6P) and to a concomitant increase in FBP, whereas the opposite was observed for fructose bisphosphatase (FBP1). Increased ALDOA activity resulted in lower FBP but elevated dihydroxyacetone phosphate (DHAP). We observed that 2,3-bisphosphoglycerate (2,3BPG) accumulated in BPGMoverexpressing cells, which likely explains their decreased glycolytic flux ( Figures 1D and 2A ). Our analysis also confirmed recently reported side products of GAPDH and pyruvate kinase (Collard et al., 2016) : we found that GAPDH overexpression induced erythronate, and PKM1 and especially PKM2 generated 2-phospholactate ( Figures S2A and S2B ). TIGARoverexpressing cells were characterized by a marked reduction of lower glycolytic intermediates, specifically 2,3BPG and phosphoenolpyruvate (PEP), but not FBP, and we did not detect any increase in hexose-phosphate species. These observations are consistent with recent evidence showing greater TIGAR phosphatase activity toward 2,3BPG and PEP than fructose-2,6-bisphosphate (Gerin et al., 2014) . Collectively, these metabolomics data support the successful induction of the desired enzymatic activities via protein overexpression, including for enzymes that did not significantly impact glycolytic flux.
In addition, our metabolite concentration data support a picture in which upper glycolytic enzymes control both glycolytic flux and metabolite levels. Overexpression of upper glycolytic enzymes caused strong metabolite changes across the entire pathway. In contrast, lower glycolytic enzymes tended to marginally increase lower glycolytic intermediates (with strong effects only on 2,3BPG) and to weakly deplete upper glycolytic intermediates (Figure 2A ). Although the overexpressed glucose and lactate transporters generally had only weak effects on metabolite concentrations, they did elevate FBP and to a lesser extent DHAP, which is linked to FBP via the reversible aldolase reaction.
Consistent with prior literature in both microbes and mammalian cells (Kochanowski et al., 2013; Kotte et al., 2010; Peeters et al., 2017; Zhang et al., 2017) , among the glycolytic intermediates FBP and DHAP concentrations correlated most strongly with glycolytic flux ( Figure 2B ). AMP, ADP, ATP, and citrate are textbook regulators of glycolysis (Berg et al., 2002; Garland et al., 1963; Llorente et al., 1970; Newsholme et al., 1977) , but none showed a comparable correlation with glycolytic flux ( Figure S2C ). With the exception of cells overexpressing toxic levels of hexokinase (see below), flux across the cell lines was generally well explained by a Michaelis-Menten function of FBP concentration (p < 10 À4 ) ( Figure 2C ). The fitted K M value of 1.5 mM (p = 0.002) is in the range of the basal FBP level in iBMK cells (1.8 mM), and the V max value of 0.3 mmol hr À1 mL cell À1 (p < 10 À8 ) is 2-fold higher than the basal glycolytic flux (0.15 mmol hr À1 mL cell À1 ) and equal to the maximum glycolytic flux obtained upon oligomycin treatment or combined GLUT3, PFKP, and MCT4 overexpression. Thus, glycolytic flux appears to be a saturable function of FBP levels.
Hexokinase Is Pro-glycolytic but Toxic in Excess
Hexokinase catalyzes an effectively irreversible step of glycolysis that has previously been shown to have significant flux control (Marín-Herná ndez et al., 2006) . HK2 overexpression resulted in accumulation of most glycolytic intermediates, including FBP ( Figure 2A ). Accordingly, we were perplexed by the negative effect of HK2 overexpression on glycolytic flux ( Figure 1D ). To address this discrepancy, we measured the temporal dynamics of glycolytic flux in HK2-overexpressing cells as well as in cells overexpressing GLUT1, GLUT3, PFKP, PFKFB3, and PKM2 ( Figures 2D and S2D ). This analysis revealed that HK2 initially accelerates glycolytic flux but suppresses it at later time points. No other enzyme showed a similar biphasic response. Thus, HK2 exerts positive glycolytic flux control, but over time also impairs glycolysis.
To obtain a better understanding of the underlying mechanism, we measured the temporal evolution of metabolite concentrations in HK2-overexpressing cells (Figures 2E and S2E ). We found that glycolytic intermediates accumulated monotonically. AMP and, to a lesser extent, ADP also built up, suggestive of energy stress. ATP levels and adenylate energy charge dropped at the same time as glycolytic flux decreased (Figures 2D and 2F) . A lower energy charge also manifested in depletion of creatine phosphate ( Figure S2F ). These metabolic alterations likely result from excessive HK2 enzyme activity detrimentally consuming ATP through overactive hexose phosphorylation, with downstream glycolysis unable to maintain pace. Cell growth and viability were, however, largely maintained over this time interval ( Figure S2G ). This HK2-induced energy stress is evocative of other instances where excessive ATP-driven phosphorylation leads to energy stress, e.g., glucose-induced ATP depletion in yeast lacking the enzyme trehalose-6-phosphate synthase (TPS1), which acts in part as a brake on hexokinase (Van Aelst et al., 1993; Ernandes et al., 1998; Gonzá lez et al., 1992) and fructose-induced drainage of ATP in hepatocytes via ketohexokinase (Abdelmalek et al., 2012; Ishimoto et al., 2012; Johnson et al., 2013) .
(B) Quality of Michaelis-Menten fit of lactate secretion rate to the individual glycolytic intermediate concentration. Lighter bars show R 2 across all overexpressed constructs and darker bars represent R 2 excluding HK2. R 2 for fits were calculated by the residual sum of squares (RSS) and total sum of squares (TSS) with R 2 = 1 À RSS/TSS. (C) Absolute glycolytic flux as a function of FBP concentration follows Michaelis-Menten kinetics (p < 10 À4 ). Dotted lines indicate fitted K M (1.5 mM; p = 0.002) and V max (0.3 mmol hr À1 mL cell À1 ; p < 10 À8 ) values. Gray represents the 95% confidence intervals of the fitted function. Data from HK2-overexpressing cells are shown as the lighter color dot and was omitted from the fitting. To prove that HK2 is fundamentally pro-glycolytic but that excessive HK2 activity causes energy stress, we transfected iBMK cells with serial dilutions of plasmid DNA encoding HK2 or, for comparison, PFKP ( Figure 2G) . Both low and high copy numbers of PFKP had similar effects, increasing glycolytic flux by $40%. In contrast, at the 30-hr time point used in Figure 1 , while concentrated HK2 decreased glycolytic flux, dilute HK2 increased glycolytic flux by $40%. Glycolytic flux began to decrease as the introduced hexokinase activity exceeded endogenous activity by more than 5-fold ( Figure S2H ). Thus, hexokinase exerts positive flux control in iBMK cells, but this was masked in our initial experiments involving massive overexpression because excessive hexokinase activity causes ATP depletion.
Hexokinase and Phosphofructokinase Also Control Flux in NIH3T3 Fibroblasts
To examine glycolytic flux control in another mouse cell line, we conducted single enzyme overexpression experiments in NIH3T3 mouse fibroblasts (3T3). Parental 3T3 cells were transduced by lentiviruses carrying a glycolytic gene of interest and lactate secretion was measured after 48 hr. Overall, the results closely mirrored those observed in iBMK cells ( Figures 3A and  S3A ). Of the eight glycolytic reactions that did not substantially control flux in iBMK cells, none had a significant effect in 3T3 cells. Similar to iBMK cells, the hexokinase and phosphofructokinase steps exerted substantial flux control, with expression of the PFK1-activator PFKFB3 yielding an effect similar to that of PFKP itself. In contrast to iBMK cells, we did not observe increased flux in response to single overexpression of glucose or lactate transporters. Overall, our results suggest that hexokinase and phosphofructokinase are common flux-controlling enzymes in glycolysis, with other core glycolytic enzymes exerting limited flux control.
Acute Ras Stimulation Transcriptionally Activates All Four Flux-Controlling Steps
The Ras/Erk pathway is a well-studied growth-promoting signal transduction pathway whose constituents are among the most frequently mutated genes in human cancers (Prior et al., 2012) . Oncogenic mutations in the Ras/Erk pathway have been shown to enhance both uptake and utilization of glucose (Flier et al., 1987; Prior et al., 2012; Racker et al., 1985; Ying et al., 2012; Yun et al., 2009) . We have previously observed that acute optogenetic stimulation of wild-type Ras is sufficient to drive 3T3 cell transcription and proliferation (Toettcher et al., 2013; Wilson et al., 2017) . We wondered whether this acute Ras-driven proliferation was associated with glycolytic enhancement, and, if so, whether the enhanced flux is driven by the flux-controlling reactions identified by our overexpression analysis.
To address these questions, we employed the optogenetic system (Opto-SOS) to activate Ras signaling in 3T3 cells . Serum-starved 3T3 cells expressing the light-activatable Opto-SOS system were stimulated with red light, and glycolytic flux was measured at 6 hr and cell growth after 24 hr ( Figure 3B ). As expected, cell growth was increased by acute Ras signaling, and even at the 6-hr time point glycolytic flux was already enhanced (Figures 3C, 3D, and S3B) .
To obtain a more thorough understanding of early metabolic perturbations upon Ras signaling, we measured glycolytic intermediates after 4 hr and 24 hr of activating light ( Figure 3E ). We observed a general increase in glycolytic intermediates and adenosine nucleotide levels at 4 hr, similar to changes observed upon HK2 overexpression in iBMK cells (Figures 2A and 3E ). FBP and DHAP were the only metabolites that remained elevated after 24 hr of Ras activation. The 2-fold elevation of FBP at 4 hr was associated with a 1.5-fold increase in glycolytic flux, consistent with the relationship between FBP and glycolytic flux in iBMK cells ( Figures 2B, 2C, 3C, and 3E) .
To explore potential mechanisms by which acute Ras activation might enhance glycolysis, we analyzed published RNAsequencing data collected from Opto-SOS 3T3 cells stimulated with activating red light over a 2-hr time course . Most gene expression changes were, as expected, in signaling pathways ( Figure S3C ). Among metabolic pathways, nucleotide biosynthesis was substantially increased, likely to support cell proliferation. In central carbon metabolism, four glycolytic genes were upregulated more than 2-fold at some time point. In contrast, such upregulation was observed for only a single gene in the pentose phosphate pathway (ribose-5-phosphate isomerase A [RPIA]) and none in the TCA cycle ( Figure S3D ). The more than 2-fold upregulated glycolytic genes were GLUT1, HK2, PFKFB3, and MCT1, corresponding to the four flux-controlling steps identified in the overexpression studies. PFKP was up to a lesser extent ( Figure 3F ). Induction of GLUT1 and HK2 was particularly strong and rapid. These acute changes differ from those resulting from chronic Ras activation, which also induces multiple lower glycolytic enzymes (Gaglio et al., 2011; Ying et al., 2012) . In addition, we observed Ras-dependent decreases in expression of some glycolytic enzymes (BPGM and PFKFB2), which were ''anti-glycolytic'' in the single enzyme overexpression experiments ( Figure 1D ). We did not observe altered expression of any glycolytic genes with low flux-control coefficients. Taken together, our results suggest that Ras controls a coordinated expression program to both up-and downregulate glycolytic enzyme targets in a manner that increases glycolytic flux. Figure 3G summarizes the flux-controlling steps identified in iBMK and 3T3 cells together with the transcriptional targets induced by acute Ras signaling.
Solid Tumors Consistently Overexpress Genes for
Glucose Transport, FBP Production, and Lactate Export Enhanced glycolysis was the first molecular phenotype assigned to cancer, and occurs in tumors originating from many different tissues and harboring distinct oncogenes and genomic alterations (Dang, 2012; Vander Heiden et al., 2009; Warburg, 1956) . We wondered whether the same four glycolytic flux-controlling steps identified in our cell culture data would also emerge in gene expression data across a variety of human tumors. To this end, we analyzed expression of glycolytic genes in 666 paired solid tumor tissue samples from The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/). Based on KEGG database annotations, we curated a set of 40 glycolytic genes, covering all isozymes of glycolytic enzymes, including PFK2 isoforms and glucose and lactate transporters Kanehisa et al., 2016 Kanehisa et al., , 2017 . Gene expression of tumor samples was normalized to the corresponding benign adjacent tissue. Unsupervised clustering of solely this limited set of glycolytic genes was sufficient to group tumor samples based on their tissue of origin ( Figures 4A and 4B) .
At least one isoform of every glycolytic step was generally upregulated in each patient tumor ( Figure 4A ). In most cancer types, strong increases were seen in at least one isoform of GLUT, of PFK (including PFK2), and of MCT, representing three of the four key flux-controlling nodes (Figures 4C and S4A) . While no hexokinase isozyme was particularly strongly expressed in lung, liver, or breast cancer, HK2 was the most strongly upregulated glycolytic enzyme in kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma tumors, and HK3 in thyroid tumors. The less consistent high upregulation of HK expression may reflect the toxicity of excess HK activity.
To more systematically evaluate overexpression at different glycolytic steps, we ranked the glycolytic gene isoforms in each individual tumor specimen based on their extent of transcriptional upregulation relative to adjacent benign tissue. Figure 4D shows the frequency with which gene isoforms catalyzing different glycolytic steps were among the four topmost upregulated glycolytic genes in a given patient. Consistent with our findings regarding flux control in cultured cells, we find that the most overexpressed glycolytic genes in human cancer encode for glucose import (GLUT1 and GLUT5), glucose phosphorylation (HK2 and HK3), FBP production (PFKFB4), PEP production (ENO2), and lactate export (MCT1 and MCT4). Except for enolase, which catalyzes the chemically challenging dehydration of 2-phosphoglycerate to PEP, these are exactly the four steps that we identified as being flux controlling in the cell culture studies.
Analysis of published gene and protein expression data in lymphocyte, macrophage, and endothelial cell activation, which are physiological contexts in which glycolysis is upregulated, also reveals a consistent upregulation of at least one isozyme catalyzing glucose uptake, glucose phosphorylation, FBP production, and lactate secretion (Jeong et al., 2017; Jha et al., 2015; Ron-Harel et al., 2016; Wang et al., 2011) (Figure S4B ). Thus, activation of glycolysis in mammals, either by physiological stimuli or cancer, is associated with induction of the four flux-controlling steps identified by the systematic overexpression analysis.
DISCUSSION
Glycolysis is the earliest described biochemical pathway. Our current understanding reflects the combined efforts of generations of scientists, with seminal contributions including Louis Pasteur's characterization of the inputs and outputs in the 1850s and Gustav Embden's outline of the reaction steps in the 1930s. Motivated in part by Otto Warburg's discovery of increased glycolytic rate in cancer in the 1920s, there is widespread and longstanding interest in understanding how flux through glycolysis is controlled. This interest is mirrored by the many thousands of studies on the topic. Nevertheless, the resulting body of primary literature is mainly composed of papers focusing on individual enzymes, with every glycolytic enzyme proposed to be rate limiting in some study, and phosphofructokinase emerging as the consensus main rate-limiting step in textbook descriptions of the pathway.
Systematic assessment of pathway regulation by metabolic control analysis, however, has revealed that rate-limiting steps are an oversimplification (Fell, 1992 (Fell, , 1998 Kacser and Burns, 1973) . Indeed, as much as every pathway step must be thermodynamically forward driven and thus consume some of the available pathway free energy, every step also exerts at least some modicum of flux control (Fell, 1998; Noor et al., 2014; Park et al., 2016) . Therefore, a pragmatic understanding of metabolic control requires figuring out which steps substantially control flux.
Here we assessed flux control in mammalian glycolysis using three approaches: glycolytic enzyme overexpression, optogenetic activation of Ras, and analysis of gene expression data from human tumors. The first of these approaches is particularly informative, as it directly probes the relationship between enzyme levels and flux, with our data covering each step of glycolysis. All three approaches consistently point to flux through glycolysis being controlled by glucose uptake and phosphorylation, FBP production, and lactate export, and not by lower glycolytic enzymes including pyruvate kinase.
Our measurements of flux control apply to the context in which the enzyme overexpression was carried out (i.e., iBMK and 3T3 cells). This reflects flux-control coefficients depending on relative enzyme concentrations. As the level or activity of an enzyme goes down (compared with pathway flux), its flux control goes up. A relatively high basal capacity for glucose transport and lactate secretion, relative to glucose phosphorylation and FBP production, likely explains why GLUT and MCT do not exert flux control in 3T3 cells. Moreover, while we do not find evidence for substantial flux control in any of the lower glycolytic enzymes, these enzymes may exert flux control in cellular contexts where their relative activities are lower. For example, aldolase A may gain flux control in contexts where it is substantially inactivated by binding to the actin cytoskeleton (Hu et al., 2016) . GAPDH, whose catalytic cysteine can be oxidized, may exert flux control in the context of oxidative stress (Liberti et al., 2017; Ralser et al., 2007 Ralser et al., , 2009 Shestov et al., 2014; Yun et al., 2015) . More generally, any enzyme of glycolysis can gain flux control if sufficiently inhibited, e.g., by genetic or pharmacological manipulation. For this reason, while studies examining the effects of enzyme depletion are valuable to understand gene essentiality, they do not shed light on intrinsic flux control (Small and Kacser, 1993a) . In contrast, for the specific cell line in which they are conducted, our overexpression studies yield quantitative estimates of flux-control coefficients.
In considering how overexpression of a single enzyme increases glycolysis, it is important to keep in mind that increased pathway flux requires enhancement of flux through every enzymatic step of the pathway (Hackett et al., 2016) . A straightforward way to achieve this is increased expression of each pathway enzyme. Overexpression of a single enzyme may, however, drive flux through upstream and downstream pathway steps by changing metabolite levels. This appears to be the case for hexokinase and phosphofructokinase. The former increases all glycolytic intermediates. The latter depletes hexose phosphates (thereby relieving product inhibition of glucose import and phosphorylation) and increases FBP and all downstream metabolites (increasing substrate to drive these reactions). It remains unclear how GLUT overexpression drives downstream glycolytic reactions (or MCT upstream ones), as neither transporter markedly alters glycolytic intermediate concentrations.
The lag between GLUT expression and flux response raises the possibility of adaptation being involved in inducing the flux increase. Consistent with this, once we include the positive fluxcontrol coefficient for hexokinase that was masked by energy stress in our initial measurements, we observe a surplus of flux control in iBMK cells (i.e., sum of flux-control coefficients greater than 1), suggesting that overexpression of certain enzymes may activate other enzymes beyond simply providing substrate or consuming product. Notably, near maximal glycolytic rate in iBMK cells is achieved by simultaneous upregulation of both FBP production and a transport step (but not by concomitant increase of both flux-controlling transport steps). The reasons for these non-linear interactions between different steps in glycolysis are not evident from the individual flux-control coefficients and are an important topic for future research.
As glycolytic rate is enhanced by overexpression of any particular flux-controlling enzyme, flux control will tend to transfer to other pathway steps. This may explain why HIF induces a broad spectrum of glycolytic enzymes including also phosphoglycerate kinase and LDH, why tumors overexpress many glycolytic enzymes including also aldolase and enolase (Graham et al., 2017; Hu et al., 2013; Nilsson et al., 2014) , and why tumor types associated with particularly high glycolytic rates due to mitochondrial defects (i.e., renal and thyroid cancer) overexpress hexokinase, even though excessive hexokinase activity can be toxic (Abu-Amero et al., 2005; Davis et al., 2014; Su et al., 2016) .
While our study does not address the extent of mitochondrial respiration in cancer cells, our finding that overexpression of certain glycolytic enzymes is sufficient to drive glycolysis without altering glucose entry into the TCA cycle is consistent with emerging evidence that control of glycolytic flux and TCA cycle flux are substantially independent (Faubert et al., 2017; Hui et al., 2017) . This reinforces the appropriateness of defining the Warburg effect as aerobic glycolysis in cancer, a robust clinical phenotype proved by fluorodeoxyglucose positron emission tomography imaging.
In summary, we provide a thorough experimental assessment of glycolytic flux control in two mammalian cell lines. We find that flux control is partially distributed, with 4 of the 13 steps collec-tively dominant. The four flux-controlling steps reside at the top (glucose import), at the two committed phosphorylation steps (hexokinase and phosphofructokinase) and at the bottom (lactate export) of glycolysis. In contrast, at least in these cells, lower glycolytic enzymes do not substantially control glycolytic flux. The identified flux-controlling enzymes stand out for being transcriptionally induced by acute Ras signaling and for being strongly upregulated in human tumors, immune cell activation, and angiogenesis, arguing for the generality of their biological importance. By providing a systematic assessment of glycolytic flux control in mammalian cells, we hope that this work helps both to contextualize research on individual glycolytic enzymes and to motivate comprehensive studies of flux control in additional pathways.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (C) Rank order of glycolytic genes from the most to the least expressed relative to benign adjacent tissue, on average, for different tumor types. Red represents highly ranked gene isoforms catalyzing glucose transport, FBP production, and lactate export for each tumor type. Black indicates the highest expressed hexokinase isoform. (D) Relative frequencies with which gene isoforms across glycolysis are among the four most upregulated glycolytic genes in an individual patient tumor. The expected frequency for each gene due to chance alone (78 occurrences across 666 tumors) is defined as a relative frequency of 1. Statistically significant enrichment of a given gene isoform in the top four most upregulated genes glycolytic genes was calculated using a Fisher's exact test with Bonferroni correction for multiple hypothesis testing. Significant enrichment was found for GLUT1, GLUT5, HK2, HK3,PFKFB4, ENO2,MCT1, and MCT4. See also Figure S4 ; Tables S2 and S3 .
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Cloning of Transient Overexpression and Lentivirus Constructs
All purchased human cDNAs of the 24 glycolytic enzymes are listed above and corresponding primers are listed in Table S1 . For cloning into the pCMV-6-A-puro mammalian expression vector, the vector was digested by HindIII (5'end) and NotI (3'end) restriction enzymes for 4.5 hr at 37 C. The digested vector was run on a 1% agarose gel (with ethidium bromide) and the cut band was gel purified using the Wizard Ò SV Gel and PCR Clean-Up System. The open reading frame (ORF) of a given gene was amplified by polymerase chain reaction (PCR) using corresponding primers and the 2x PfuUltra II Hotstart PCR Master Mix according to manufacturer's instructions. PCR products were cleaned up with the Wizard Ò SV Gel and PCR Clean-Up System before Gibson Assembly. For all Gibson Assembly reactions, a molar ratio of 1:3 (vector:insert) was used and the reaction was performed at 50 C for 1 hr as per manufacturer's instructions. Assembled constructs were transformed into NEB 5-alpha competent E. coli cells and grown on agar plates (100 mg/mL ampicilin) at 37 C overnight. Single colonies were inoculated in Luria broth (100 mg/mL ampicilin) overnight and plasmid DNA was extracted using the QIAprep Spin Miniprep Kit. Constructs were sequence verified by Sanger sequencing (Genewiz, South Plainfield, NJ, USA) and stocks for all experiments were prepared using the QIAGEN Maxi Kit. For lentivirus transductions, ORFs were cloned into a pHR' SFFVp lentiviral vector, upstream of IRES CIBN-BFP-CAAX, using the In-Fusion Ò HD Cloning Kit according to the manufacturer's instructions. Briefly, the vector was linearized by backbone PCR and the ORFs were amplified by PCR as described above. The linearized vector and PCR products were run on a 1% agarose gel (with ethidium bromide) and the cut bands were cleaned up with the WizardÒ SV Gel and PCR Clean-Up System. Using a molar ratio of 1:3 (vector:insert), all In-Fusion reactions were performed at 50 C for 15 min as per manufacturer's instructions. Assembled constructs were transformed into Clontech Stellar competent E. coli cells and grown on agar plates (50 mg/mL carbenicillin) at 37 C overnight. Single colonies were inoculated in Luria broth (50 mg/mL carbenicillin) overnight. Plasmid DNA was prepared by the QIAprep Spin Miniprep Kit and constructs were sequence verified by Sanger sequencing (Genewiz, South Plainfield, NJ, USA).
Transient Overexpression of Glycolytic Genes in iBMK Cells iBMK cells were transfected using Lipofectamine 2000 as described in the manufacturer's protocol. 24 hr before transfection, 0.5 ml packed cell volume (PCV) iBMK cells were plated per well in a 6-well plate in DMEM (10% dFBS). For each well, 2.5 mg of plasmid DNA, 10 ml of transfection reagent and 200 ml of OptiMEM were used. The DNA to lipofectamine ratio was kept equal for all experiments. For coexpression experiments, the total amount of plasmid DNA was 2.5 mg and the amount of the different constructs was kept equivalent. The single expression controls were adjusted to the lowest concentration and mixed with vector plasmid DNA to keep the total amount of plasmid DNA at 2.5 mg. Correspondingly, serial dilutions of a given construct were supplemented with vector plasmid DNA to keep the 2.5 mg total plasmid DNA amount. iBMK cells were incubated with the plasmid DNA-lipofectamine complexes in 2 ml DMEM (10% dFBS) for 6 hr before switching to fresh DMEM (10% dFBS). Metabolomics experiments were performed in 6 cm dishes. For transfection in 6 cm dishes, 1 ml PCV iBMK cells were plated and grown overnight before transfection with 8 mg of plasmid DNA, 20 ml of lipofectamine as well as 500 ml of OptiMEM incubated in 5 ml of DMEM (10% dFBS) for 6 hr.
Number of viable cells was counted at the indicated time points. Cells were transfected in 6-well plates as described above and viable cells were counted using Trypan blue exclusion assays and a Countess TM II FL Automated Cell Counter (ThermoFisher, MA).
Western Blotting iBMK cells were collected at the indicated time points after transfection. Cells were washed once with ice cold 1x PBS and scraped into 200 ml RIPA buffer supplemented with phosphatase and protease inhibitors. Collected iBMK cells were vortexed, incubated for 10 min on ice and centrifuged at 17,000 g at 4 C. Supernatant was transferred to a fresh tube and protein content was determined by PierceÔ BCA Protein Assay Kit. 10 mg of protein per sample was analyzed by SDS-PAGE and western blotting. Primary and secondary antibodies (horse-radish peroxidase conjugated) were used at 1:1000 and 1:10,000 respectively. The SuperSignalÔ ELISA Pico Chemiluminescent Substrate was used for protein detection.
Glycolytic Flux Measurements
Glucose and lactate measurements were performed in 6-well plates between 24 hr and 30 hr post transfection unless stated otherwise. Cells were washed twice with 2 ml of 1x PBS before 1 ml of fresh DMEM (10% dFBS) was added. After 6 hr of incubation, 300 ml of supernatant was collected and analyzed by a YSI 2900D Biochemistry Analyzer (YSI, Yellow Springs, OH, USA). Measured glucose consumption and lactate secretion were normalized to the average PCV during the 6 hr measurement interval as determined based on the terminal PCV measurement at 30 hr and the known growth rate (0.028 h -1 ) of GFP expressing cells ( Figure S1A ):
PCV Average = 1 0:028h À1 PCV End À PCV End e 0:028h À1 3 6h 6h (Equation 3) Measurement of the secreted lactate to consumed glucose ratio was done in 5 mM glucose conditions. To make growth medium with 5 mM glucose, DMEM powder without glucose, glutamine, or phenol red was dissolved in deionized water and supplemented with L-glutamine (0.584 g/l), phenol red (0.015 g/l), sodium bicarbonate (3.7 g/l), glucose (0.9 g/l) and 10% dFBS. Data was presented either as absolute values or the percentage change normalized to the vector control as indicated in the corresponding figure panels.
Measurement of Oxygen Consumption Rates
Oxygen consumption rates were measured using a Seahorse XF24 extracellular flux analyzer (Agilent, Santa Clara, CA). Briefly, 100 ml of a 0.5 ml cells ml -1 solution were plated per well in a XF24 cell culture microplate. The next day, cells were transfected with Vector, GFP, GLUT3, PFKP, GAPDH, PKM2, LDHA and MCT4 constructs as described above. 24 hr post transfection, cells were equilibrated for 1 hr in DMEM supplemented with 25 mM glucose and L-glutamine (0.584 g/l) in a non-CO 2 incubator. Oxygen consumption rates were monitored at baseline (5 measurements) and were normalized to cell number as determined by the CyQUANT Cell Proliferation Assay Kit. Experiments were performed with four replicates per overexpression condition and the average of three independent ex-! (Equation 2) Equation 2 is shown in Figure 1A . C J E for a given overexpressed enzyme E were calculated using Equation 2 based on the determined fold-change in lactate secretion f J E = J E =J Vector from experiments performed in 25 mM glucose conditions. Results were presented as the mean with 95% confidence intervals from nR6 biological replicates of at least two independent experiments. For the calculation of the sum of determined C J E in iBMK cells, only constructs exhibiting positive flux control in both 5 mM and 25 mM glucose conditions were considered:
whereby C J E for different gene isoforms acting on the same glycolytic step were averaged: 
Oligomycin Treatment
Analogous to the transient overexpression experiments, 0.5 ml PCV iBMK cells were plated per well of a 6-well plate in DMEM (10% dFBS) the day before the experiment. The next day, iBMK cells were washed twice with 1x PBS and incubated with 1 ml of fresh DMEM (10% dFBS) supplemented with 1 mM oligomycin. Supernatant was analyzed after 6 hr of incubation and measured lactate was normalized to PCV. Data was presented as the percentage change in lactate secretion compared to vector control.
